XML 27 R6.htm IDEA: XBRL DOCUMENT v3.8.0.1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Cash flows from operating activities:    
Net loss $ (22,686) $ (22,046)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 2,151 1,182
Amortization of deferred financing costs and debt discount 707 954
Joint venture acquisition obligation accretion 0 24
Provision for expired inventory 340 172
Share-based compensation expense 753 1,080
Gain on asset disposal (42) (127)
Increases (decreases) in cash caused by changes in operating assets and liabilities:    
Accounts receivable 1,129 (179)
Inventories 251 471
Other current assets (593) 633
Other assets (94) (764)
Accounts payable and accrued expenses (1,817) (673)
Deferred revenues (3) (8)
Long-term deferred rent 90 (252)
Net cash used in operating activities (18,128) (19,533)
Cash flows from investing activities:    
Purchases of property and equipment /long-lived assets (295) (67)
Proceeds from sale of assets 113 131
Change in restricted cash (325) 0
Net cash (used in) provided by investing activities (1,708) 64
Cash flows from financing activities:    
Principal payments on long-term obligations (4,720) 0
Joint venture purchase payments 0 (1,774)
Proceeds from sale of common stock 23,613 21,467
Costs from sale of common stock (2,078) (2,084)
Net cash provided by financing activities 16,815 17,609
Effect of exchange rate changes on cash and cash equivalents 11 82
Net decrease in cash and cash equivalents (3,010) (1,778)
Cash and cash equivalents at beginning of period 12,560 14,338
Cash and cash equivalents at end of period 9,550 12,560
Cash paid during period for:    
Interest 1,364 1,618
Supplemental schedule of non-cash investing and financing activities:    
Issuance costs paid in common stock 0 189
Conversion of preferred stock into common stock 23 0
Fair value of Series B Convertible Preferred Stock beneficial conversion feature 3,977 0
Azaya Therapeutics, Inc. [Member]    
Adjustments to reconcile net loss to net cash used in operating activities:    
In process research and development acquired from Azaya Therapeutics 1,686 0
Cash flows from investing activities:    
Purchases of property and equipment /long-lived assets (1,201) 0
Supplemental schedule of non-cash investing and financing activities:    
Common stock issued in payment for the assets acquired $ 2,311 $ 0